Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/denali-therapeutics">Denali Therapeutics</a> Discovering and developing therapies for patients with neurodegenerative diseases. Private 2015 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/symbiota-0">Symbiota</a> Pioneering microbial solutions to naturally promote plant health. Private 2013 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/ecosense-lighting%C2%AE">EcoSense Lighting®</a> Providing best-in-class LED lighting solutions for use in commercial and architectural applications. Private 2013 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Leading genome editing company translating its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases. Private 2013 View Profile
<a href="/venture-capital/all-companies/be-power-tech">Be Power Tech</a> Pioneering energy-efficient climate control through the development of natural gas-powered air conditioners that also generate electricity. Private 2015 View Profile
<a href="/venture-capital/all-companies/evelo-therapeutics">Evelo Therapeutics</a> Transforming cancer therapy through a deep understanding of the cancer microbiome. Private 2015 View Profile
<a href="/venture-capital/all-companies/codiak-biosciences">Codiak BioSciences</a> Leading developer of exosome-based diagnostics and therapeutics. Private 2015 View Profile
<a href="/venture-capital/all-companies/kaleido-biosciences">Kaleido BioSciences</a> Private 2015 View Profile
<a href="/venture-capital/all-companies/epiva-biosciences">Epiva BioSciences</a> Private 2015 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. Public 2006 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile
<a href="/venture-capital/all-companies/seres-therapeutics">Seres Therapeutics</a> Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. Public 2012 View Profile